Literature DB >> 27217411

Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators.

Montserrat Baldan-Martin1, Laura Mourino-Alvarez1, Laura Gonzalez-Calero1, Rafael Moreno-Luna1, Tamara Sastre-Oliva1, Gema Ruiz-Hurtado1, Julian Segura1, Juan Antonio Lopez1, Jesus Vazquez1, Fernando Vivanco1, Gloria Alvarez-Llamas1, Luis M Ruilope2, Fernando de la Cuesta1, Maria G Barderas2.   

Abstract

Albuminuria is a risk factor strongly associated with cardiovascular disease, the first cause of death in the general population. It is well established that renin-angiotensin system suppressors prevent the development of new-onset albuminuria in naïf hypertensive patients and diminish its excretion, but we cannot forget the percentage of hypertensive patients who develop de novo albuminuria. Here, we applied multiple proteomic strategy with the purpose to elucidate specific molecular pathways involved in the pathogenesis and provide predictors and chronic organ damage indicators. Briefly, 1143 patients were followed up for a minimum period of 3 years. One hundred and twenty-nine hypertensive patients chronically renin-angiotensin system suppressed were recruited, classified in 3 different groups depending on their albuminuria levels (normoalbuminuria, de novo albuminuria, and sustained albuminuria), and investigated by multiple proteomic strategies. Our strategy allowed us to perform one of the deepest plasma proteomic analysis to date, which has shown 2 proteomic signatures: (1) with predictive value of de novo albuminuria and (2) sustained albuminuria indicator proteins. These proteins are involved in inflammation, immune as well as in the proteasome activation occurring in situations of endoplasmic reticulum stress. Furthermore, these results open the possibility of a future strategy based on anti-immune therapy to treat hypertension which could help to prevent the development of albuminuria and, hence, the progression of kidney damage.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  albuminuria; cause of death; hypertension; immune system; renin–angiotensin system

Mesh:

Year:  2016        PMID: 27217411     DOI: 10.1161/HYPERTENSIONAHA.116.07412

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

Review 1.  Application of omics in hypertension and resistant hypertension.

Authors:  Jiuqi Guo; Xiaofan Guo; Yingxian Sun; Zhao Li; Pengyu Jia
Journal:  Hypertens Res       Date:  2022-03-09       Impact factor: 3.872

2.  Development and validation of a decision tree classification model for the essential hypertension based on serum protein biomarkers.

Authors:  Zongqiang Han; Lina Wen
Journal:  Ann Transl Med       Date:  2022-09

3.  Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria.

Authors:  Marta Martin-Lorenzo; Laura Gonzalez-Calero; Paula J Martinez; Montserrat Baldan-Martin; Juan Antonio Lopez; Gema Ruiz-Hurtado; Fernando de la Cuesta; Julián Segura; Jesús Vazquez; Fernando Vivanco; Maria G Barderas; Luis M Ruilope; Gloria Alvarez-Llamas
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

4.  Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria.

Authors:  Fernando de la Cuesta; Montserrat Baldan-Martin; Rafael Moreno-Luna; Gloria Alvarez-Llamas; Laura Gonzalez-Calero; Laura Mourino-Alvarez; Tamara Sastre-Oliva; Juan A López; Jesús Vázquez; Gema Ruiz-Hurtado; Julian Segura; Fernando Vivanco; Luis M Ruilope; Maria G Barderas
Journal:  Oncotarget       Date:  2017-02-28

5.  Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria.

Authors:  Laura Gonzalez-Calero; Paula J Martínez; Marta Martin-Lorenzo; Montserrat Baldan-Martin; Gema Ruiz-Hurtado; Fernando de la Cuesta; Eva Calvo; Julian Segura; Juan Antonio Lopez; Jesús Vázquez; Maria G Barderas; Luis M Ruilope; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Oncotarget       Date:  2017-07-04

6.  Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals.

Authors:  Montserrat Baldan-Martin; Juan A Lopez; Nerea Corbacho-Alonso; Paula J Martinez; Elena Rodriguez-Sanchez; Laura Mourino-Alvarez; Tamara Sastre-Oliva; Tatiana Martin-Rojas; Raul Rincón; Eva Calvo; Jesus Vazquez; Fernando Vivanco; Luis R Padial; Gloria Alvarez-Llamas; Gema Ruiz-Hurtado; Luis M Ruilope; Maria G Barderas
Journal:  Sci Rep       Date:  2018-03-19       Impact factor: 4.379

Review 7.  Utilizing proteomics to understand and define hypertension: where are we and where do we go?

Authors:  Christian Delles; Emma Carrick; Delyth Graham; Stuart A Nicklin
Journal:  Expert Rev Proteomics       Date:  2018-07-12       Impact factor: 3.940

8.  Identification of Urinary Biomarkers for Exercise-Induced Immunosuppression by iTRAQ Proteomics.

Authors:  Guoqin Xu; Wentao Lin; Andrew J McAinch; Xu Yan; Xiquan Weng
Journal:  Biomed Res Int       Date:  2020-01-23       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.